Favourable West Nile vaccine results
Friday, 27 February, 2009
Early results from a Phase I safety and efficacy trial of a West Nile virus vaccine, being developed by Acuvax’s US affiliate Hawaii Biotech, are “stunning”, the company said.
The results will enable an easier roll-out for a dengue fever vaccine, Acuvax’s CEO Dr William Ardrey said in a statement.
Hawaii Biotech, a private company in which Acuvax has a substantial shareholding, is trialling its vaccine in 24 healthy volunteers to check safety and antibody development.
All volunteers showed the presence of neutralizing antibodies. The vaccine is based on a proprietary recombinant DNA technology platform, which is being used by Hawaii to develop a vaccine for dengue fever, as well as candidates for malaria, tick-borne encephalitis virus and flu.
The company will now begin trials in children, the elderly and immuno-compromised patients.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
